Abstract: Disclosed herein are self-degradable microneedle devices for the controlled-release of an immunotherapeutic agent. Also disclosed are methods for treating a disease (for example, cancer) using a self-degradable microneedle patch for the sustained delivery of an immunotherapeutic agent (for example, a PD1 antibody).

Abstract: Embodiments of the present disclosure relate generally to photoimmunotherapy for treating cancer. More particularly, the present disclosure provides photo-responsive dermal applicators that use transdermal microneedle arrays to administer an immunogenic composition and a photo-sensitive biological pigment to a subject to treat and/or prevent cancer. Photo-responsive dermal applicators of the present disclosure provide the ability to target cancerous tumors in a manner that is safer and less invasive than conventional means.

Abstract: The present disclosure relates to microneedle devices and methods for treating a disease (for example, diabetes) using a degradable cross-linked gel for self-regulated delivery of a therapeutic agent (for example, insulin).

Abstract: Disclosed herein are microneedle devices, kits comprising the microneedle devices, and methods of using the microneedle devices. Specifically, disclosed is a device for transport of a material across a biological barrier of a subject comprising: a plurality of microneedles each having a base end and a tip, with at least one pathway disposed at or between the base end and the tip; a substrate to which the base ends of the microneedles are attached or integrated; and at least one reservoir which is in connection with the base ends of the microneedles array, wherein the reservoir comprises an agent delivery system, wherein the agent delivery system comprises an agent to be transported across the biological barrier, or a means for producing an agent to be transported across the biological barrier, and a means for detecting a physiological signal from the recipient.

Abstract: The present disclosure relates to microneedle devices and methods for treating a disease (for example, diabetes) using a degradable cross-linked gel for self-regulated delivery of a therapeutic agent (for example, insulin).

Abstract: The present invention belongs to the field of heat treatment for metal plate strips, and discloses a water spray system for heat treatment of metal plate strips and a control method. The system comprises a shunt water collector, sub-water supply pipelines, a control valve group and a control system. The control method comprises a water pressure regulating method and a water flow regulating method. The shunt water collector adopts multi-pipeline uniform flow design and realizes uniform shunt and constant pressure water supply. The sub-water supply pipelines are designed with three configuration modes of a control valve group in accordance with varieties and specifications of metal plate strips, rhythms of production and heat treatment technologies to realize dual closed-loop control of water pressure-water flow.

Abstract: The present disclosure relates to nanoparticles, controlled-release dosage forms, and methods for the administration of an immunotherapeutic agent.

Abstract: The present invention belongs to the field of heat treatment for metal plate strips, and discloses a water spray system for heat treatment of metal plate strips and a control method. The system comprises a shunt water collector, sub-water supply pipelines, a control valve group and a control system. The control method comprises a water pressure regulating method and a water flow regulating method. The shunt water collector adopts multi-pipeline uniform flow design and realizes uniform shunt and constant pressure water supply. The sub-water supply pipelines are designed with three configuration modes of a control valve group in accordance with varieties and specifications of metal plate strips, rhythms of production and heat treatment technologies to realize dual closed-loop control of water pressure-water flow.

Abstract: The present disclosure relates to nanoparticles, controlled-release dosage forms, and methods for the administration of an immunotherapeutic agent.

Abstract: Disclosed herein are microneedle devices, kits comprising the microneedle devices, and methods of using the microneedle devices. Specifically, disclosed is a device for transport of a material across a biological barrier of a subject comprising: a plurality of microneedles each having a base end and a tip, with at least one pathway disposed at or between the base end and the tip; a substrate to which the base ends of the microneedles are attached or integrated; and at least one reservoir which is in connection with the base ends of the microneedles array, wherein the reservoir comprises an agent delivery system, wherein the agent delivery system comprises an agent to be transported across the biological barrier, or a means for producing an agent to be transported across the biological barrier, and a means for detecting a physiological signal from the recipient.

Abstract: Embodiments of the present disclosure relate generally to photoimmunotherapy for treating cancer. More particularly, the present disclosure provides photo-responsive dermal applicators that use transdermal microneedle arrays to administer an immunogenic composition and a photo-sensitive biological pigment to a subject to treat and/or prevent cancer. Photo-responsive dermal applicators of the present disclosure provide the ability to target cancerous tumors in a manner that is safer and less invasive than conventional means.

Abstract: Disclosed herein are microneedle devices, kits comprising the microneedle devices, and methods of using the microneedle devices. Specifically, disclosed is a device for transport of a material across a biological barrier of a subject comprising: a plurality of microneedles each having a base end and a tip, with at least one pathway disposed at or between the base end and the tip; a substrate to which the base ends of the microneedles are attached or integrated; and at least one reservoir which is in connection with the base ends of the microneedles array, wherein the reservoir comprises an agent delivery system, wherein the agent delivery system comprises an agent to be transported across the biological barrier, or a means for producing an agent to be transported across the biological barrier, and a means for detecting a physiological signal from the recipient.

Abstract: Disclosed are engineered nanovesicles and engineered platelets comprising an exogenous protein and methods for treating cancer comprising administering the same to a subject.

Abstract: The present disclosure relates to microneedle devices and methods for treating a disease (for example, diabetes) using a degradable cross-linked gel for self-regulated delivery of a therapeutic agent (for example, insulin).

Abstract: Disclosed herein are microneedle devices, kits comprising the microneedle devices, and methods of using the microneedle devices. Specifically, disclosed is a device for transport of a material across a biological barrier of a subject comprising: a plurality of microneedles each having a base end and a tip, with at least one pathway disposed at or between the base end and the tip; a substrate to which the base ends of the microneedles are attached or integrated; and at least one reservoir which is in connection with the base ends of the microneedles array, wherein the reservoir comprises an agent delivery system, wherein the agent delivery system comprises an agent to be transported across the biological barrier, or a means for producing an agent to be transported across the biological barrier, and a means for detecting a physiological signal from the recipient.

Abstract: Disclosed herein are self-degradable microneedle devices for the controlled-release of an immunotherapeutic agent. Also disclosed are methods for treating a disease (for example, cancer) using a self-degradable microneedle patch for the sustained delivery of an immunotherapeutic agent (for example, a PD1 antibody).

Abstract: The present disclosure relates to nanoparticles, controlled-release dosage forms, and methods for the administration of an immunotherapeutic agent.